knowledge -WSS

knowledge

author：explore 2025-10-01 23:01:52 - browse：82873

In 2018, New York University became the first U.S. medical school to go tuition free. Since then, a handful of others have followed with many more considering similar programs. One hope for free tuition endeavors is that lower post-graduation debt will increase the number of med students who choose lower-paying, desperately needed careers in primary care and pediatrics. But free tuition programs are not necessarily delivering on that promise.

In this episode of the First Opinion Podcast, University of Pennsylvania oncologist and researcher Ezekiel Emanuel and Matthew Guido, a project manager in the Healthcare Transformation Institute, discuss their original research on tuition-free programs with former host Pat Skerrett, who is filling in while Torie Bosch is on maternity leave. They make the case that medical school debt is only one of many factors that influence new doctors to choose less-popular specialties and geographic locations for their residencies. Other factors including prestige, the lifetime earning potential of higher-pay specialties, which can add several millions dollars over a career, can have more sway than student debt alone. This is especially important, they say, as needs for patients with chronic illnesses are rapidly outpacing the number of primary care physicians available to give that care.

“We have undervalued both philosophically and also financially the complications of managing chronic illness,” Emanuel says. “Can we rebalance the payment system that rewards the improvements in health and therefore the attention to chronic illness through primary care?”

You can read more about Emanuel and Guido’s opinions in their essay “Free med school tuition won’t solve the shortage of primary care physicians.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Experts study whether long Covid risk adds up with each reinfection

WSS

Flagship Pioneering launches a new biotech in two countries

Intarcia’s device

Readout LOUD podcast: possible new ALS drug, artificial wombs

FDA investigates CAR

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

The EPA's new lead rule: How one expert crunched the numbers

leisure time

knowledge

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Disappointing trial forces Pfizer to pivot on obesity medicine plans

As demand for Covid shots wanes, Moderna seeks its next success

Despite FDA concern, risk that CAR

In age of alternative facts, a scholarly course on calling out crap

Cigna, Humana reportedly in talks to merge

Medicare proposal to cover medical devices draws a mixed reaction

Biotech lab space demand falls sharply

23andMe had bad news about my health. I wish a person had delivered it

Emergency workers more likely to restrain Black patients: study

Wikipedia

Senate HELP committee spars over health care workforce policies

Biotech stock slump in 2023: awaiting the turnaround

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

UnitedHealth’s Optum accused of antitrust violations in California

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Flagship Pioneering launches a new biotech in two countries

entertainment

Wikipedia

Wikipedia

focus